Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS -Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study
Journal of Clinical Oncology · 2023
DOI: 10.1200/jco.22.02018 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von Filippo de Braud und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Exanthema. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
PURPOSE No approved targeted therapy for the treatment of patients with neuroblastoma RAS viral (v-ras) oncogene homolog ( NRAS)–mutant melanoma is currently available. PATIENTS AND METHODS In this phase Ib escalation/expansion study (ClinicalTrials.gov identifier: NCT02974725 ), the safety, tolerability, and preliminary antitumor activity of naporafenib (LXH254), a BRAF/CRAF protein kinases inhibitor, were explored in combination with trametinib in patients with advanced/metastatic KRAS- or BRAF-mutant non–small-cell lung cancer (escalation arm) or NRAS-mutant melanoma (escalation and expansion arms). RESULTS Thirty-six and 30 patients were enrolled in escalation and expansion, respectively. During escalation, six patients reported grade ≥3 dose-limiting toxicities, including dermatitis acneiform (n = 2), maculopapular rash (n = 2), increased lipase (n = 1), and Stevens-Johnson syndrome (n = 1). The recommended doses for expansion were naporafenib 200 mg twice a day plus trametinib 1 mg once daily and naporafenib 400 mg twice a day plus trametinib 0.5 mg once daily. During expansion, all 30 patients experienced a treatment-related adverse event, the most common being rash (80%, n = 24), blood creatine phosphokinase increased, diarrhea, and nausea (30%, n = 9 each). In expansion, the objective response rate, median duration of response, and median progression-free survival were 46.7% (95% CI, 21.3 to 73.4; 7 of 15 patients), 3.75 (95% CI, 1.97 to not estimable [NE]) months, and 5.52 months, respectively, in patients treated with naporafenib 200 mg twice a day plus trametinib 1 mg once daily, and 13.3% (95% CI, 1.7 to 40.5; 2 of 15 patients), 3.75 (95% CI, 2.04 to NE) months, and 4.21 months, respectively, in patients treated with naporafenib 400 mg twice a day plus trametinib 0.5 mg once daily. CONCLUSION Naporafenib plus trametinib showed promising preliminary antitumor activity in patients with NRAS-mutant melanoma. Prophylactic strategies aimed to lower the incidence of skin-related events are under investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy.
- Medical Oncology and Hematology Department, Istituto Nazionale dei Tumori, Milan, Italy.
- University Hospitals Leuven, Leuven, Belgium.
- Cancer Center, Massachusetts General Hospital, Boston, MA.
- Department of Dermato-Oncology and CIC, AP-HP Hôpital Saint Louis, Université Paris Cité, Inserm U976, Paris, France.
- NCT/UCC Early Clinical Trial Unit, Technical University Dresden, Dresden, Germany.
ORCID-Profile: Rebecca S Heist, Celeste Lebbe, Martin Wermke, Dirk Schadendorf, Piotr Rutkowski, Jürgen Wolf, Paolo A Ascierto, Ignacio Gil-Bazo, Shumei Kato, Meredith McKean, Eva Muñoz Couselo, Armando Santoro, Jaeyeon Kim, Michele Moschetta, Adil Daud
Zitieren
APA
de Braud, F., Dooms, C., Heist, R. S., Lebbe, C., Wermke, M., Gazzah, A., Schadendorf, D., Rutkowski, P., Wolf, J., Ascierto, P. A., Gil-Bazo, I., Kato, S., Wolodarski, M., McKean, M., Muñoz Couselo, E., Sebastian, M., Santoro, A., Cooke, V., Manganelli, L., …, & Daud, A. (2023). Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS -Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.22.02018
Vancouver
de Braud F, Dooms C, Heist RS, Lebbe C, Wermke M, Gazzah A, et al. Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS -Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study. Journal of Clinical Oncology. 2023. doi:10.1200/jco.22.02018
BibTeX
@article{deBraud2023,
author = {de Braud, Filippo and Dooms, Christophe and Heist, Rebecca S and Lebbe, Celeste and Wermke, Martin and Gazzah, Anas and Schadendorf, Dirk and Rutkowski, Piotr and Wolf, Jürgen and Ascierto, Paolo A and Gil-Bazo, Ignacio and Kato, Shumei and Wolodarski, Maria and McKean, Meredith and Muñoz Couselo, Eva and Sebastian, Martin and Santoro, Armando and Cooke, Vesselina and Manganelli, Luca and Wan, Kitty and Gaur, Anil and Kim, Jaeyeon and Caponigro, Giordano and Couillebault, Xuân-Mai and Evans, Helen and Campbell, Catarina D and Basu, Sumit and Moschetta, Michele and Daud, Adil},
title = {Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS -Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study},
journal = {Journal of Clinical Oncology},
year = {2023},
doi = {10.1200/jco.22.02018}
}
EUVIMED